Compare Avantis International Small Cap Value ETF (AVDV) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Cytokinetics Inc — how do they compare? Avantis International Small Cap Value ETF trades at $109.58, while Cytokinetics Inc trades at $77.39 (market cap $10.78B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| AVDV | CYTK | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $110.40 | $87.26 |
52-Week Low | $83.89 | $34.31 |
Market Cap | — | $10.78B |
Enterprise Value | — | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $109.63, up 1.34% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI. The stock has delivered strong returns recently, including a 35% gain highlighted in June 2026 news, and offers a dividend with a payment scheduled for June 2026. However, key valuation ratios such as P/E and P/B are unavailable, limiting fundamental clarity.
The outlook is mixed: technical strength and positive media coverage on international small-cap value performance support upside, but overbought RSI levels and missing financial metrics pose risks. Investors should weigh the ETF's exposure to developed markets outside the U.S. against potential volatility from commodity sectors, as noted in recent analysis.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
